

Tech guy here. There’s no way in hell a new system would be mainframe-based. A distributed queue with delivery receipt and many nodes to process messages along with many distributed read-only DBs is the way to scale this thing. And you can be isolated form local power and connectivity issues. Tech isn’t the problem in this situation, market penetration is.
It wasn’t the US last time but ok. Neither of the two big MRNA vaccine producers were US.
Tell me you’re USanian without telling me.